French nuclear reactor business Framatome and Korea Hydro & Nuclear Power (KHNP) have signed a memorandum of understanding to demonstrate the feasibility of producing non-carrier added lutetium-177 (Lu-177) – a medical radioisotope used for a variety of lifesaving cancer treatments – at the Wolsong nuclear power station in South Korea.

Under the MoU, Framatome and KHNP will jointly perform a technical assessment at Wolsong using Framatome’s radioisotope production technology. Framatome said the technology has been used successfully on a commercial production level at the Bruce Power nuclear power station in Canada.